» Articles » PMID: 10700683

Influence of Timing and Dose of Thyroid Hormone Replacement on Development in Infants with Congenital Hypothyroidism

Overview
Journal J Pediatr
Specialty Pediatrics
Date 2000 Mar 4
PMID 10700683
Citations 41
Authors
Affiliations
Soon will be listed here.
Abstract

Objectives: To test whether early treatment with a high initial dose of levothyroxine can prevent suboptimal mental development in all neonates with congenital hypothyroidism (CH).

Study Design: Sixty-one patients, 27 with severe CH and 34 with mild CH, were treated either early (<13 days) or late (> or =13 days) with either a high initial dose of levothyroxine (> or =9.5 microg/kg/d) or a low initial dose (<9.5 microg/kg/d). With these criteria, 4 treatment groups were formed. The results of the Bayley test, performed at the age of 10 to 30 months and expressed as mental developmental index (MDI) and psychomotor developmental index (PDI), were related to socioeconomic status, treatment group, initial free thyroxine (FT(4)) concentration, and mean FT(4) concentration during the first 3 months of treatment (FT(4)-A) and the ensuing 9 months (FT(4)-B).

Results: Mean (+/- SD) MDI was 113 +/- 14, and mean PDI was 114 +/- 12. In the severe CH group, only the patients treated early with a high initial dose had normal MDI scores (124 +/- 16), whereas the scores of the other groups ranged from 97 to 103. In contrast, all patients in the mild CH group had normal scores (range, 122-125), except those in the group treated late with a low initial dose, whose score was 110 +/- 10. Forty-three percent of the variance in MDI and PDI scores was explained by treatment factors, such as the treatment group, initial FT(4) concentration, FT(4)-A, and FT(4)-B.

Conclusions: Our data suggest that optimal treatment includes achievement of euthyroidism before the third week of life by initiation of therapy before 13 days with a levothyroxine dose above 9.5 microg/kg/d and maintenance of FT(4) concentrations in the upper normal range during the first year. Thus treated, patients with CH can achieve normal psychomotor development at 10 to 30 months, irrespective of the severity of the disease.

Citing Articles

Efficacy of levothyroxine on growth and development in children with congenital hypothyroidism: A meta-analysis.

Liang W, Tu L Medicine (Baltimore). 2025; 104(8):e41499.

PMID: 39993126 PMC: 11856982. DOI: 10.1097/MD.0000000000041499.


Analysis of motor, cognitive and language performance of infants undergoing treatment for congenital hypothyroidism.

Romero M, Goto M, dOuro M, Lima M, Dutra V, Mendes-Dos-Santos C J Pediatr (Rio J). 2024; 101(2):172-178.

PMID: 39396810 PMC: 11889671. DOI: 10.1016/j.jped.2024.08.008.


Primary congenital hypothyroidism: challenges in a low-income country without paediatric endocrinologist and universal newborn screening.

Bin S, Phou K, Im S BMJ Case Rep. 2023; 16(5).

PMID: 37137550 PMC: 10163418. DOI: 10.1136/bcr-2022-249997.


Knowns and unknowns about congenital hypothyroidism: 2022 update.

Itonaga T, Hasegawa Y, Higuchi S, Satoh M, Sawada H, Shimura K Clin Pediatr Endocrinol. 2023; 32(1):11-25.

PMID: 36761498 PMC: 9887299. DOI: 10.1297/cpe.2022-0016.


Basal Serum Thyroxine Level should Guide Initial Thyroxine Replacement Dose in Neonates with Congenital Hypothyroidism.

Gunbey C, Ozon A, Gonc E, Alikasifoglu A, Karahan S, Kandemir N J Clin Res Pediatr Endocrinol. 2020; 13(3):269-275.

PMID: 33374096 PMC: 8388053. DOI: 10.4274/jcrpe.galenos.2020.2020.0194.